RenovoRx regains Nasdaq minimum bid price compliance

RenovoRx, Inc. (NASDAQ: RNXT) announced it has received written notification from Nasdaq confirming the company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Nasdaq's Listing Qualifications Staff notified RenovoRx on Aug. 20, 2026, that the closing bid price of its common stock was at $1.00 per share or greater for 10 consecutive business days from Aug. 6 through Aug. 19, 2026. The company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq confirmed the matter is closed. RenovoRx had originally received a deficiency notice from Nasdaq on Dec. 31, 2025.

The notification has no effect on the trading of the company's common stock, which continues to trade under the symbol "RNXT."

In a statement, Chief Executive Officer Shaun Bagai cited recent business developments, including record second-quarter revenue, growth in active commercial cancer center customers for its RenovoCath device, the first commercial clinical use of RenovoCath in a sarcoma patient, and completion of enrollment in the company's Phase III TIGeR-PaC trial.

RenovoRx reported approximately $1.1 million in RenovoCath sales for its first full year of commercial efforts in 2025, followed by quarterly revenue of $909,000 in the second quarter of 2026. The company said it completed enrollment in the TIGeR-PaC trial in August 2026, with trial completion expected in the first half of 2027 and topline data readout expected in the second half of 2027.

You May Also Be Interested In

• Coinbase expands board to ten with appointment of Anthony Armstrong
• Greenland Mines closes Sarfartoq rare earth acquisition in Greenland
• Shell completes $16.5B acquisition of ARC Resources